{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1340","value":"1063"},{"groupId":"OG001","spread":"826","value":"2390"},{"groupId":"OG002","spread":"3228","value":"3875"},{"groupId":"OG003","spread":"6842","value":"6587"},{"groupId":"OG004","spread":"7503","value":"13544"},{"groupId":"OG005","spread":"8248","value":"14258"},{"groupId":"OG006","spread":"12425","value":"30571"},{"groupId":"OG007","spread":"16960","value":"30386"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2289","value":"1933"},{"groupId":"OG001","spread":"1132","value":"2955"},{"groupId":"OG002","spread":"4827","value":"5573"},{"groupId":"OG003","spread":"11656","value":"10369"},{"groupId":"OG004","spread":"10505","value":"18707"},{"groupId":"OG005","spread":"15370","value":"23109"},{"groupId":"OG006","spread":"20288","value":"48183"},{"groupId":"OG007","spread":"24852","value":"39609"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"40"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"PBD conjugated Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1540","value":"1185"},{"groupId":"OG001","spread":"1136","value":"3194"},{"groupId":"OG002","spread":"4334","value":"5032"},{"groupId":"OG003","spread":"9108","value":"8869"},{"groupId":"OG004","spread":"7649","value":"15980"},{"groupId":"OG005","spread":"9745","value":"16973"},{"groupId":"OG006","spread":"14888","value":"33834"},{"groupId":"OG007","spread":"20829","value":"36099"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"41"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"title":"total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2576","value":"1924"},{"groupId":"OG001","spread":"1725","value":"3986"},{"groupId":"OG002","spread":"6882","value":"7958"},{"groupId":"OG003","spread":"15704","value":"14025"},{"groupId":"OG004","spread":"13513","value":"23428"},{"groupId":"OG005","spread":"19457","value":"28657"},{"groupId":"OG006","spread":"26899","value":"57450"},{"groupId":"OG007","spread":"31012","value":"49892"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"39"},{"groupId":"OG005","value":"72"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"title":"total Ab: Cycle 2"},{"categories":[{"measurements":[{"comment":"Standard deviation could not be determined as only one participant had evaluable data.","groupId":"OG003","spread":"NA","value":"0.00213"},{"groupId":"OG004","spread":"0.00671","value":"0.00462"},{"groupId":"OG005","spread":"0.0423","value":"0.0222"},{"groupId":"OG006","spread":"0.0303","value":"0.0174"},{"groupId":"OG007","spread":"0.0959","value":"0.0436"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"16"}],"units":"Participants"}],"title":"SG3199: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"0.0234","value":"0.0242"},{"groupId":"OG004","spread":"0.286","value":"0.154"},{"groupId":"OG005","spread":"0.0248","value":"0.0108"},{"groupId":"OG006","spread":"0.00461","value":"0.00425"},{"groupId":"OG007","spread":"0.00215","value":"0.00332"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"title":"SG3199: Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"42"},{"groupId":"OG005","value":"88"},{"groupId":"OG006","value":"14"},{"groupId":"OG007","value":"22"}],"units":"Participants"}],"description":"AUClast for Pyrrolobenzodiazepine (PBD) conjugated antibody (Ab), total Ab and free warhead (SG3199).\n\nResults for Part 1 and Part 2 have been pooled for the same dosage and schedule, as specified in the protocol.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (15 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG000","title":"Part 1: 15 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (30 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG001","title":"Part 1: 30 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (60 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG002","title":"Part 1: 60 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (90 μg/kg) on Day 1 of each 3 week cycle (Q3W).","id":"OG003","title":"Part 1: 90 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (120 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG004","title":"Parts 1 and 2: 120 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (150 μg/kg) on Day 1 of each 3 week cycle (Q3W). Parts 1 and 2 are pooled for PK analysis as specified in the protocol.","id":"OG005","title":"Parts 1 and 2: 150 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 3 week cycle (Q3W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG006","title":"Part 1: 200 μg/kg Q3W"},{"description":"Participants received an intravenous (IV) infusion of ADCT-402 (200 μg/kg) on Day 1 of each 6 week cycle (Q6W). Analysis was performed separately for Q3W and Q6W treatment cycles as specified in the protocol.","id":"OG007","title":"Part 1: 200 μg/kg Q6W"}],"paramType":"MEAN","populationDescription":"Only participants with evaluable pharmacokinetic (PK) results were included in the analysis. Where data is not presented, the PK profiles were non-measurable or short-lived in duration; therefore, no analysis could be performed.","reportingStatus":"POSTED","timeFrame":"Q3W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (3 weeks cycle); Q6W schedule: Day 1 (pre-dose and 1 to 6 hours post-dose), and days 2, 3, 5, 8, 15 and 21 of Cycles 1 and 2 (6 week cycle)","title":"Area Under the Serum Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for ADCT-402","type":"SECONDARY","unitOfMeasure":"day*ng/mL"}